266 related articles for article (PubMed ID: 25569009)
1. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.
Huh WK; Ault KA; Chelmow D; Davey DD; Goulart RA; Garcia FAR; Kinney WK; Massad LS; Mayeaux EJ; Saslow D; Schiffman M; Wentzensen N; Lawson HW; Einstein MH
Obstet Gynecol; 2015 Feb; 125(2):330-337. PubMed ID: 25569009
[TBL] [Abstract][Full Text] [Related]
2. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.
Huh WK; Ault KA; Chelmow D; Davey DD; Goulart RA; Garcia FA; Kinney WK; Massad LS; Mayeaux EJ; Saslow D; Schiffman M; Wentzensen N; Lawson HW; Einstein MH
Gynecol Oncol; 2015 Feb; 136(2):178-82. PubMed ID: 25579107
[TBL] [Abstract][Full Text] [Related]
3. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.
Huh WK; Ault KA; Chelmow D; Davey DD; Goulart RA; Garcia FA; Kinney WK; Massad LS; Mayeaux EJ; Saslow D; Schiffman M; Wentzensen N; Lawson HW; Einstein MH
J Low Genit Tract Dis; 2015 Apr; 19(2):91-6. PubMed ID: 25574659
[TBL] [Abstract][Full Text] [Related]
4. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
5. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society.
Fontham ETH; Wolf AMD; Church TR; Etzioni R; Flowers CR; Herzig A; Guerra CE; Oeffinger KC; Shih YT; Walter LC; Kim JJ; Andrews KS; DeSantis CE; Fedewa SA; Manassaram-Baptiste D; Saslow D; Wender RC; Smith RA
CA Cancer J Clin; 2020 Sep; 70(5):321-346. PubMed ID: 32729638
[TBL] [Abstract][Full Text] [Related]
6. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.
Saslow D; Solomon D; Lawson HW; Killackey M; Kulasingam SL; Cain J; Garcia FA; Moriarty AT; Waxman AG; Wilbur DC; Wentzensen N; Downs LS; Spitzer M; Moscicki AB; Franco EL; Stoler MH; Schiffman M; Castle PE; Myers ER;
CA Cancer J Clin; 2012; 62(3):147-72. PubMed ID: 22422631
[TBL] [Abstract][Full Text] [Related]
7. Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions.
Zhou H; Mody RR; Luna E; Armylagos D; Xu J; Schwartz MR; Mody DR; Ge Y
Cancer Cytopathol; 2016 May; 124(5):317-23. PubMed ID: 26774025
[TBL] [Abstract][Full Text] [Related]
8. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.
Saslow D; Solomon D; Lawson HW; Killackey M; Kulasingam SL; Cain J; Garcia FA; Moriarty AT; Waxman AG; Wilbur DC; Wentzensen N; Downs LS; Spitzer M; Moscicki AB; Franco EL; Stoler MH; Schiffman M; Castle PE; Myers ER; ; ;
Am J Clin Pathol; 2012 Apr; 137(4):516-42. PubMed ID: 22431528
[TBL] [Abstract][Full Text] [Related]
9. Management of HPV-positive women in cervical screening using results from two consecutive screening rounds.
Polman NJ; Veldhuijzen NJ; Heideman DAM; Snijders PJF; Meijer CJLM; Berkhof J
Int J Cancer; 2019 May; 144(9):2339-2346. PubMed ID: 30565673
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis.
Berkhof J; de Bruijne MC; Zielinski GD; Bulkmans NW; Rozendaal L; Snijders PJ; Verheijen RH; Meijer CJ
Int J Cancer; 2006 Apr; 118(7):1759-68. PubMed ID: 16217759
[TBL] [Abstract][Full Text] [Related]
11. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cytology, HPV DNA testing and HPV 16/18 genotyping alone or combined targeting to the more balanced methodology for cervical cancer screening.
Chatzistamatiou K; Moysiadis T; Moschaki V; Panteleris N; Agorastos T
Gynecol Oncol; 2016 Jul; 142(1):120-127. PubMed ID: 27126005
[TBL] [Abstract][Full Text] [Related]
13. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population].
Zhao YQ; Dai Y; Dang L; Kong LH; Zhang Y; Feng RM; Qiao YL; Lang JH
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):764-771. PubMed ID: 30392341
[No Abstract] [Full Text] [Related]
14. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
15. Primary HPV testing verification: A retrospective ad-hoc analysis of screening algorithms on women doubly tested for cytology and HPV.
Tracht J; Wrenn A; Eltoum IE
Diagn Cytopathol; 2017 Jul; 45(7):580-586. PubMed ID: 28436211
[TBL] [Abstract][Full Text] [Related]
16. The ideal strategy for cervical cancer screening in Japan: Result from the Fukui Cervical Cancer Screening Study.
Kurokawa T; Onuma T; Shinagawa A; Chino Y; Kobayashi M; Yoshida Y
Cytopathology; 2018 Aug; 29(4):361-367. PubMed ID: 29768678
[TBL] [Abstract][Full Text] [Related]
17. Testing for cervical cancer: new recommendations from the American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology.
CA Cancer J Clin; 2012; 62(3):211-2. PubMed ID: 22418892
[No Abstract] [Full Text] [Related]
18. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.
Zhang J; Zhao Y; Dai Y; Dang L; Ma L; Yang C; Li Y; Kong L; Wei L; Zhang S; Liu J; Xi M; Chen L; Duan X; Xiao Q; Abulizi G; Zhang G; Hong Y; Gao X; Zhou Q; Xie X; Li L; Niyazi M; Zhang Z; Tuo J; Ding Y; Si M; Chen F; Song L; Qiao Y; Lang J
JAMA Oncol; 2021 Feb; 7(2):263-270. PubMed ID: 33377903
[TBL] [Abstract][Full Text] [Related]
19. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
20. Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland.
Veijalainen O; Kares S; Kotaniemi-Talonen L; Kujala P; Vuento R; Luukkaala T; Kholová I; Mäenpää J
Acta Obstet Gynecol Scand; 2021 Mar; 100(3):403-409. PubMed ID: 33037625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
